TCRX
TSCAN THERAPEUTICS, INC.Marquee-fund ownership over time
This quarter's activity
New positions opened
None.
Positions exited
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Renaissance Technologies | Q3 2024(8Q snapshot) | 7Q | $5.92 | $1.00 | -83% |
| Citadel Advisors re-entered | Q3 2024(8Q snapshot) | 7Q | $5.63 | $1.00 | -82% |
| Millennium Management re-entered | Q3 2024(8Q snapshot) | 7Q | $5.63 | $1.00 | -82% |
| Two Sigma Investments re-entered | Q4 2024(8Q snapshot) | 6Q | $4.82 | $1.00 | -79% |
| D.E. Shaw | Q1 2026(8Q snapshot) | 1Q | $0.98 | $1.00 | +3% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Point72 Asset Management | Q1 2026 | Q2 2026 | → $1.00 | +3% |
| AQR Capital Management 2× in & out | Q3 2025 | Q4 2025 | → $1.10 | -39% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at TScan Therapeutics, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from May 22, 2026 — the most recent Form 4 on file — not from today.
- Form 40001193125-26-236870May 22, 2026
- Form 40001193125-26-236855May 22, 2026
- Form 40001193125-26-236854May 22, 2026
- Form 40001193125-26-236848May 22, 2026
- Form 40001193125-26-236844May 22, 2026
- Form 40001193125-26-236841May 22, 2026
- Form 40001193125-26-019729Jan 22, 2026
- Form 40001193125-26-019723Jan 22, 2026
- Form 40001193125-26-019702Jan 22, 2026
- Form 40001193125-26-019697Jan 22, 2026
- Form 40001193125-26-019674Jan 22, 2026
- Form 40000902664-25-005396Dec 23, 2025
- Form 40000950170-25-093232Jul 2, 2025
- Form 40000950170-25-093058Jul 2, 2025
- Form 40000950170-25-093057Jul 2, 2025
Fundamentals
XBRL · TSCAN THERAPEUTICS, INC.Annual figures sourced directly from TSCAN THERAPEUTICS, INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for TScan Therapeutics, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KMaterial eventMay 22, 2026
- 10-QQuarterly reportMay 6, 2026
- 8-KMaterial eventMay 6, 2026
- DEF 14AProxy statementApr 17, 2026
- 8-KMaterial eventApr 2, 2026
- 10-KAnnual reportMar 4, 2026
- 8-KMaterial eventMar 4, 2026
- 8-KMaterial eventJan 12, 2026
- 8-KMaterial eventNov 26, 2025
- 10-QQuarterly reportNov 12, 2025
- 8-KMaterial eventNov 12, 2025
- 8-KMaterial eventNov 3, 2025
- 8-KMaterial eventSep 9, 2025
- 8-KMaterial eventAug 20, 2025
- 10-QQuarterly reportAug 12, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| D.E. Shaw | Q1 2026 | open | $0.98 | $1.00 | +3% |
| Point72 Asset Management | Q1 2026 | Q2 2026 | $0.98 | $1.00 | +3% |
| AQR Capital Management | Q3 2025 | Q4 2025 | $1.81 | $1.10 | -39% |
| Two Sigma Investments | Q2 2025 | open | $1.31 | $1.00 | -24% |
| Millennium Management | Q2 2025 | open | $1.31 | $1.00 | -24% |
| Citadel Advisors | Q1 2025 | open | $2.05 | $1.00 | -51% |
| Two Sigma Investments | Q4 2024 | Q1 2025 | $4.82 | $2.05 | -57% |
| AQR Capital Management | Q4 2024 | Q1 2025 | $4.82 | $2.05 | -57% |
| Citadel Advisors | Q3 2024 | Q4 2024 | $5.63 | $4.82 | -14% |
| Millennium Management | Q3 2024 | Q1 2025 | $5.63 | $2.05 | -64% |
| Renaissance Technologies | Q3 2024 | open | $5.92 | $1.00 | -83% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.